II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX: II) today announced that it is sponsoring a symposium on �The Science of Electroceuticals�.� The meeting to discuss this new scientific discipline will be held on December 19, 2006 from 10:00 a.m. to 1:30 p.m. EST at The Corporate Auditorium in the McGraw-Hill Building, 1221 Avenue of the Americas, New York, New York. Noted researchers, physicians and scientists will share their knowledge and experience about this paradigm-shifting approach to non-invasive electrotherapeutic intervention. Keynote speakers will include Louis Ignarro, Ph.D, Nobel Laureate; Arthur Pilla, Ph.D, Technology Originator; Michael Shen, MD, Cardiologist - Cleveland Clinic; and Berish Strauch, MD, Surgeon and Researcher. �We are honored and excited to have such distinguished speakers join us for this event,� said Andre� DiMino, Vice Chairman and Co-CEO of Ivivi Technologies. �We believe that it is important that the healthcare community gain a better understanding of how Electroceuticals� are playing a role in treating injured soft tissue and reducing related pain." Symposium attendance is limited and reservations are required. Please contact either Ed Hammel, Executive Vice President of Ivivi Technologies, at 201-784-8168 or Alison Ziegler of Cameron Associates at 212-554-5469. The Company will webcast The Science of Electroceuticals� Symposium on December 19, 2006 beginning at 10:00 a.m. EST and interested parties are invited to listen to the presentations live over the Internet at http://www.wsw.com/webcast/ii/ or http://www.ivivitechnologies.com. To listen to the live call, go to the website at least 10 minutes early to download and install any necessary audio software. A replay will also be available. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This press release contains �forward looking statements� that are subject to risk and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. These risks could cause actual results to differ materially from those expressed in any forward looking statements made by, or on behalf of, the Company. The Company assumes no obligation to update the information contained in this press release. Ivivi Technologies, Inc. (AMEX: II) today announced that it is sponsoring a symposium on "The Science of Electroceuticals(TM)." The meeting to discuss this new scientific discipline will be held on December 19, 2006 from 10:00 a.m. to 1:30 p.m. EST at The Corporate Auditorium in the McGraw-Hill Building, 1221 Avenue of the Americas, New York, New York. Noted researchers, physicians and scientists will share their knowledge and experience about this paradigm-shifting approach to non-invasive electrotherapeutic intervention. Keynote speakers will include Louis Ignarro, Ph.D, Nobel Laureate; Arthur Pilla, Ph.D, Technology Originator; Michael Shen, MD, Cardiologist - Cleveland Clinic; and Berish Strauch, MD, Surgeon and Researcher. "We are honored and excited to have such distinguished speakers join us for this event," said Andre' DiMino, Vice Chairman and Co-CEO of Ivivi Technologies. "We believe that it is important that the healthcare community gain a better understanding of how Electroceuticals(TM) are playing a role in treating injured soft tissue and reducing related pain." Symposium attendance is limited and reservations are required. Please contact either Ed Hammel, Executive Vice President of Ivivi Technologies, at 201-784-8168 or Alison Ziegler of Cameron Associates at 212-554-5469. The Company will webcast The Science of Electroceuticals(TM) Symposium on December 19, 2006 beginning at 10:00 a.m. EST and interested parties are invited to listen to the presentations live over the Internet at http://www.wsw.com/webcast/ii/ or http://www.ivivitechnologies.com. To listen to the live call, go to the website at least 10 minutes early to download and install any necessary audio software. A replay will also be available. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(TM) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This press release contains "forward looking statements" that are subject to risk and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's registration statement on Form SB-2. These risks could cause actual results to differ materially from those expressed in any forward looking statements made by, or on behalf of, the Company. The Company assumes no obligation to update the information contained in this press release.